Sexual Health Sexual Health Society
Publishing on sexual health from the widest perspective
RESEARCH ARTICLE

Syncope as a probable side effect to combination antiretroviral therapy initiated during primary HIV-1 infection

Dorte Lybaek A B and Carsten Schade Larsen A

A Department of Infectious Diseases, Skejby Hospital, University Hospital of Aarhus, DK-8200 Aarhus N, Denmark.

B Corresponding author. Email: dlybaek@dadlnet.dk

Sexual Health 5(1) 69-71 http://dx.doi.org/10.1071/SH07088
Submitted: 2 November 2007  Accepted: 22 January 2008   Published: 22 February 2008

Abstract

A previously healthy young man experienced several episodes of syncope while being treated with tenofovir, emtricitabine and nevirapine initiated during primary HIV-1 infection. Symptoms disappeared after discontinuation of antiretroviral therapy and we suggest that syncope may be a side effect to one of the three antiretroviral drugs that has not been described previously.


References

[1]  Kinloch-de Loes S 2006 Treatment of acute HIV-1 infection: is it coming of age? J Infect Dis 194 721 4 doi:10.1086/506625

[2]  Gerstoft J , Mathiesen L , Lundgren JD , Nielsen HI , Pedersen C , Obel N , et al Retningslinier for HIV-behandling; 2006. Available online at: http://www.dsinfm.dk [verified February 2008].

[3]  van Leth F Phanuphak P Ruxrungtham K Baraldi E Miller S Gazzard B et al 2004 Comparison of first-line antiretroviral therapy with regimens including nevirapine, efavirenz, or both drugs, plus stavudine and lamivudine: a randomised open-label trial, the 2NN Study. Lancet 363 1253 63 doi:10.1016/S0140-6736(04)15997-7

[4]  Adkins JC Noble S 1998 Efavirenz. Drugs 56 1055 64 doi:10.2165/00003495-199856060-00014

[5]  Frampton JE Perry CM 2005 Emtricitabine: a review of its use in the management of HIV infection. Drugs 65 1427 48 doi:10.2165/00003495-200565100-00008

[6]  Saag MS Chan P Raffi F Wolff M Pearce D Molina JM et al 2004 Efficacy and safety of emtricitabine vs stavudine in combination therapy in antiretroviral-naive patients. JAMA 292 180 90 doi:10.1001/jama.292.2.180

[7]  Mira JA Lozano F Santos J Ramayo E Terrón A Palacios R et al 2004 Gynaecomastia in HIV-infected men on highly active antiretroviral therapy: association with efavirenz and didanosine treatment. Antivir Ther 9 511 17

[8]  Strub C Kaufmann GR Flepp. M Egger M Kahlert C Cavassini M et al 2004 Gynaecomastia and antiretroviral therapy. AIDS 18 1347 9
doi:10.1097/00002030-200406180-00019

[9]  Smith DE Walker BD Cooper DA Rosenberg ES Kaldor JM 2004 Is antiretroviral treatment of primary HIV infection clinically justified on the basis of current evidence? AIDS 18 709 18 doi:10.1097/00002030-200403260-00001

[10]  Hecht FM Wang L Collier A Little S Markowitz M Margolick J et al 2006 A multicenter observational study of the potential benefits of initiating combination antiretroviral therapy during acute HIV infection. J Infect Dis 194 725 33 doi:10.1086/506616

[11]  Streeck H Jessen H Alter G Teigen N Waring MT Jessen A et al 2006 Immunological and virological impact of highly active antiretroviral therapy initiated during acute HIV-1 infection. J Infect Dis 194 734 9 doi:10.1086/503811

[12]  Steingrover R , Bezemer D , Fernandez Garcia E , Kroon F , de Wolf F , Prins M , et al Early treatment of primary HIV-1 infection lowers the viral set point. 14th Conference on Retroviruses and Opportunistic Infections; 2007 Feb 25–28; Los Angeles, CA, USA. CROI 2007. Available online at: http://www.retroconference.org/2007/abstract [verified February 2008]. Abstract 124LB.

[13]  Koegl C , Wolf E , Jessen H , Schewe K , Rausch M , Goelz J , et al No benefit from early treatment in primary HIV-infection? 14th Conference on Retroviruses and Opportunistic Infections; 2007 Feb 25–28; Los Angeles, CA, USA. CROI 2007. Available online at: http://www.retroconference.org/2007/abstract [verified February 2008]. Abstract 125LB.

[14]  Hammer SM Saag MS Schechter M Montaner JSG Schooley RT Jacobsen DM et al 2006 Treatment for adult HIV infection. 2006 recommendations of the International AIDS Society-USA panel. JAMA 296 251 65 doi:10.1001/jama.296.3.251

[15]  Bartlett JG , Lane HC , Pau AK , Anderson J , Baker AC , Bozzette SA , et al Guidelines for the use of antiretroviral agents in HIV-1-infected adults and adolescents. Recommendations of the Panel on Clinical Practices for Treatment of HIV; October 2006: 1–121. Department Health and Human Services.

[16]  Gazzard B on behalf of the BHIVA writing Committee. 2006 British HIV association (BHIVA) guidelines for the treatment of HIV-infected adults with antiretroviral therapy (2006). HIV Med 7 487 503 doi:10.1111/j.1468-1293.2006.00424.x



Export Citation